Crossmark

Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio

Crossref DOI link: https://doi.org/10.1016/j.rce.2025.502370

Published Print: 2025-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Villanueva, B.

Figueras, A.

Torres-Iglesias, R.

Muñoz, M.

Moreno-Lopes, S.

Trullén-Malaret, N.

Martínez, A.

Viñals, F.

Riera-Mestre, A. https://orcid.org/0000-0001-9411-804X
Funding

Funding for this research was provided by:

Carlos III Health Institute
License Information

Text and Data Mining valid from 2025-10-01

Text and Data Mining valid from 2025-10-01

Version of Record valid from 2025-09-22
More Information

This article is maintained by: Elsevier

Article Title: Evolución de biomarcadores de angiogénesis e inflamación en pacientes con telangiectasia hemorrágica hereditaria durante el tratamiento con bevacizumab: protocolo de estudio

Journal Title: Revista Clínica Española

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rce.2025.502370

Content Type: article

Copyright: © 2025 The Authors. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below